Key Abstracts in Renal Cell Carcinoma From ASCO GU 2023

Matthew Zibelman, MD


March 10, 2023

The ASCO Genitourinary Cancers Symposium 2023 featured several important presentations on renal cell carcinoma (RCC).

Dr Matthew Zibelman, from Fox Chase Cancer Center in Philadelphia, begins by discussing the results of the phase 3 ZIRCON trial, which used radiolabeled girentuximab in PET/CT imaging to differentiate small renal cell masses as clear cell RCC, nonclear cell RCC, or benign tumors. The study met its primary endpoint, indicating a potentially useful noninvasive test for the diagnosis of small renal tumors.

Next, Dr Zibelman reports on an update of the phase 3 CheckMate 9ER trial in which patients received either the combination of cabozantinib and nivolumab or sunitinib for frontline therapy of metastatic RCC. After 3 years of follow-up, the combination showed an almost doubling of median progression-free survival.

Finally, Dr Zibelman discusses the phase 3 COSMIC-313 trial comparing the addition of cabozantinib to nivolumab and ipilimumab vs nivolumab and ipilimumab alone for patients with intermediate- or poor-risk metastatic RCC and who had not received prior therapy.

Progression-free survival improved in the experimental arm, but in a post-hoc analysis, no benefit was shown for the poor-risk group. Dr Zibelman noted that frontline triple therapy does not yet seem appropriate for patients with metastatic RCC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.